A Multicenter, Single Arm, Open-Label PhIV Study to Investigate the Effect of First-Line Herceptin (Trastuzumab) in Combination With a Taxane in Patients With Metastatic Breast Cancer Who Relapsed After Receiving (Neo)Adjuvant Herceptin for HER2-Positive Early Breast Cancer
Phase of Trial: Phase IV
Latest Information Update: 03 Jan 2017
At a glance
- Drugs Trastuzumab (Primary) ; Docetaxel; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Roche
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 23 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 19 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.